Homocysteine inhibits inactivation of factor Va by activated protein C - PubMed (original) (raw)

. 2001 Feb 9;276(6):4389-97.

doi: 10.1074/jbc.M004124200. Epub 2000 Nov 16.

Affiliations

• PMID: 11083858
• DOI: 10.1074/jbc.M004124200

Free article

Homocysteine inhibits inactivation of factor Va by activated protein C

A Undas et al. J Biol Chem. 2001.

Free article

Abstract

We report the effect of homocysteine on the inactivation of factor Va by activated protein C (APC) using clotting assays, immunoblotting, and radiolabeling experiments. Homocysteine, cysteine, or homocysteine thiolactone have no effect on factor V activation by alpha-thrombin. Factor Va derived from homocysteine-treated factor V was inactivated by APC at a reduced rate. The inactivation impairment increased with increasing homocysteine concentration (pseudo first order rate k = 1.2, 0.9, 0.7, 0.4 min(-1) at 0, 0.03, 0.1, 1 mm homocysteine, respectively). Neither cysteine nor homocysteine thiolactone treatment of factor V affected APC inactivation of derived factor Va. Western blot analyses of APC inactivation of homocysteine-modified factor Va are consistent with the results of clotting assays. Factor Va, derived from factor V treated with 1 mm beta-mercaptoethanol was inactivated more rapidly than the untreated protein sample. Factor V incubated with [(35)S]homocysteine (10-450 micrometer) incorporated label within 5 min, which was found only in those fragments that contained free sulfhydryl groups: the light chain (Cys-1960, Cys-2113), the B region (Cys-1085), and the 26/28-kDa (residues 507-709) APC cleavage products of the heavy chain (Cys-539, Cys-585). Treatment with beta-mercaptoethanol removed all radiolabel. Plasma of patients assessed to be hyperhomocysteinemic showed APC resistance in a clot-based assay. Our results indicate that homocysteine rapidly incorporates into factor V and that the prothrombotic tendency in hyperhomocysteinemia may be related to impaired inactivation of factor Va by APC due to homocysteinylation of the cofactor by modification of free cysteine(s).

PubMed Disclaimer

Similar articles

• Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.
  Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Nicolaes GA, et al. J Biol Chem. 1995 Sep 8;270(36):21158-66. doi: 10.1074/jbc.270.36.21158. J Biol Chem. 1995. PMID: 7673148
• Protein C activation and factor Va inactivation on human umbilical vein endothelial cells.
  Hockin MF, Kalafatis M, Shatos M, Mann KG. Hockin MF, et al. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2765-75. doi: 10.1161/01.atv.17.11.2765. Arterioscler Thromb Vasc Biol. 1997. PMID: 9409254
• The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals.
  Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. Camire RM, et al. J Biol Chem. 1995 Sep 1;270(35):20794-800. doi: 10.1074/jbc.270.35.20794. J Biol Chem. 1995. PMID: 7657663
• Mechanisms that regulate the anticoagulant function of coagulation factor V.
  Thorelli E. Thorelli E. Scand J Clin Lab Invest Suppl. 1999;229:19-26. doi: 10.1080/00365519950185913. Scand J Clin Lab Invest Suppl. 1999. PMID: 10097286 Review.
• Factor V and protein S as cofactors to activated protein C.
  Dahlbäck B. Dahlbäck B. Haematologica. 1997 Jan-Feb;82(1):91-5. Haematologica. 1997. PMID: 9107093 Review.

Cited by

• Liver Cirrhosis Patients Homozygous for MTHFR C677T Develop Portal Vein Thrombosis 8 Years Earlier Than Wild Type.
  Ames PRJ, D'Andrea G, Arcaro A, Marottoli V, Iannaccone L, Maraglione M, Gentile F. Ames PRJ, et al. Dig Dis Sci. 2023 Apr;68(4):1332-1338. doi: 10.1007/s10620-022-07666-7. Epub 2022 Aug 24. Dig Dis Sci. 2023. PMID: 35999432
• The role of methylenetetrahydrofolate reductase C677T gene polymorphism as a risk factor for coronary artery disease: a cross-sectional study in the Sidoarjo Regional General Hospital.
  Sugijo H, Sargowo D, Widjajanto E, Romdoni R. Sugijo H, et al. Pan Afr Med J. 2022 Mar 15;41:212. doi: 10.11604/pamj.2022.41.212.24916. eCollection 2022. Pan Afr Med J. 2022. PMID: 35721657 Free PMC article.
• Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia: a case series.
  Ammouri W, Tazi ZM, Harmouche H, Maamar M, Adnaoui M. Ammouri W, et al. J Med Case Rep. 2017 Sep 2;11(1):250. doi: 10.1186/s13256-017-1415-z. J Med Case Rep. 2017. PMID: 28863787 Free PMC article.
• Hyperhomocysteinemia exacerbates Alzheimer's disease pathology by way of the β-amyloid fibrinogen interaction.
  Chung YC, Kruyer A, Yao Y, Feierman E, Richards A, Strickland S, Norris EH. Chung YC, et al. J Thromb Haemost. 2016 Jul;14(7):1442-52. doi: 10.1111/jth.13340. Epub 2016 Jun 13. J Thromb Haemost. 2016. PMID: 27090576 Free PMC article.
• The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients.
  Kedzierska M, Malinowska J, Glowacki R, Olas B, Bald E, Jeziorski A, Piekarski J. Kedzierska M, et al. Mol Cell Biochem. 2011 Sep;355(1-2):193-9. doi: 10.1007/s11010-011-0854-x. Epub 2011 May 1. Mol Cell Biochem. 2011. PMID: 21533764

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Miscellaneous

  • NCI CPTAC Assay Portal